RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hubei Biocause Pharmaceutical Co Stock

Hubei Biocause Pharmaceutical Co Equity 2024

Hubei Biocause Pharmaceutical Co Equity

20.59 B CNY

Ticker

000627.SZ

ISIN

CNE000000F48

In 2024, Hubei Biocause Pharmaceutical Co's equity was 20.59 B CNY, a -3.84% increase from the 21.41 B CNY equity in the previous year.

Hubei Biocause Pharmaceutical Co Aktienanalyse

What does Hubei Biocause Pharmaceutical Co do?

Hubei Biocause Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Hubei Biocause Pharmaceutical Co's Equity

Hubei Biocause Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Hubei Biocause Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Hubei Biocause Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Hubei Biocause Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Hubei Biocause Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Hubei Biocause Pharmaceutical Co stock

What is the equity of Hubei Biocause Pharmaceutical Co this year?

Hubei Biocause Pharmaceutical Co has equity of 20.59 B CNY this year.

What was the equity of Hubei Biocause Pharmaceutical Co compared to the previous year?

The equity of Hubei Biocause Pharmaceutical Co has increased/decreased by -3.84% decreased compared to the previous year.

What impact does a high equity have on investors of Hubei Biocause Pharmaceutical Co?

A high equity is advantageous for investors of Hubei Biocause Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Hubei Biocause Pharmaceutical Co?

A low equity can be a risk for investors of Hubei Biocause Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Hubei Biocause Pharmaceutical Co affect the company?

An increase in equity of Hubei Biocause Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Hubei Biocause Pharmaceutical Co affect the company?

A reduction in equity of Hubei Biocause Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Hubei Biocause Pharmaceutical Co?

Some factors that can affect the equity of Hubei Biocause Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Hubei Biocause Pharmaceutical Co so important for investors?

The equity of Hubei Biocause Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Hubei Biocause Pharmaceutical Co take to change the equity?

To change equity, Hubei Biocause Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Hubei Biocause Pharmaceutical Co pay?

Over the past 12 months, Hubei Biocause Pharmaceutical Co paid a dividend of 0.11 CNY . This corresponds to a dividend yield of about 4.17 %. For the coming 12 months, Hubei Biocause Pharmaceutical Co is expected to pay a dividend of 0.11 CNY.

What is the dividend yield of Hubei Biocause Pharmaceutical Co?

The current dividend yield of Hubei Biocause Pharmaceutical Co is 4.17 %.

When does Hubei Biocause Pharmaceutical Co pay dividends?

Hubei Biocause Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, July, June.

How secure is the dividend of Hubei Biocause Pharmaceutical Co?

Hubei Biocause Pharmaceutical Co paid dividends every year for the past 8 years.

What is the dividend of Hubei Biocause Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0.11 CNY are expected. This corresponds to a dividend yield of 4.17 %.

In which sector is Hubei Biocause Pharmaceutical Co located?

Hubei Biocause Pharmaceutical Co is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Hubei Biocause Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Biocause Pharmaceutical Co from 5/30/2023 amounting to 0.11 CNY, you needed to have the stock in your portfolio before the ex-date on 5/30/2023.

When did Hubei Biocause Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 5/30/2023.

What was the dividend of Hubei Biocause Pharmaceutical Co in the year 2023?

In the year 2023, Hubei Biocause Pharmaceutical Co distributed 0.005 CNY as dividends.

In which currency does Hubei Biocause Pharmaceutical Co pay out the dividend?

The dividends of Hubei Biocause Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hubei Biocause Pharmaceutical Co

Our stock analysis for Hubei Biocause Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Biocause Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.